Literature DB >> 16946484

Crystallization and preliminary crystallographic analysis of the tetrameric form of phosphofructokinase-2 from Escherichia coli, a member of the ribokinase family.

Ricardo Cabrera1, Andrés Caniuguir, Andre L B Ambrosio, Victoria Guixé, Richard C Garratt, Jorge Babul.   

Abstract

Escherichia coli contains two phosphofructokinases, Pfk-1 and Pfk-2, which belong to unrelated protein families. In addition to catalytic function, the enzymes have converged in showing substrate inhibition by the nucleotide MgATP. However, although both Pfk-1 and Pfk-2 have been extensively characterized biochemically, only the structure of the former has been solved by X-ray diffraction. In order to fully understand how the same function has evolved on different structural folds, Pfk-2 has been crystallized by the hanging-drop vapour-diffusion method using PEG 6000 as precipitant. Single crystals were grown in the presence of MgATP and diffracted to 1.98 A. The crystals belong to the orthorhombic system, space group P222(1), with unit-cell parameters a = 42.8, b = 86.8, c = 171.3 A. The calculated Matthews coefficient of 2.45 A(3) Da(-1) indicates the presence of two monomers in the asymmetric unit, corresponding to a solvent content of 49%. Structure determination is ongoing.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16946484      PMCID: PMC2242871          DOI: 10.1107/S1744309106032246

Source DB:  PubMed          Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun        ISSN: 1744-3091


  16 in total

1.  The Protein Data Bank.

Authors:  H M Berman; J Westbrook; Z Feng; G Gilliland; T N Bhat; H Weissig; I N Shindyalov; P E Bourne
Journal:  Nucleic Acids Res       Date:  2000-01-01       Impact factor: 16.971

Review 2.  The biochemical properties and phylogenies of phosphofructokinases from extremophiles.

Authors:  R S Ronimus; H W Morgan
Journal:  Extremophiles       Date:  2001-12       Impact factor: 2.395

3.  The mechanism of ATP inhibition of wild type and mutant phosphofructo-1-kinase from Escherichia coli.

Authors:  R L Zheng; R G Kemp
Journal:  J Biol Chem       Date:  1992-11-25       Impact factor: 5.157

4.  Structural basis of the allosteric behaviour of phosphofructokinase.

Authors:  T Schirmer; P R Evans
Journal:  Nature       Date:  1990-01-11       Impact factor: 49.962

5.  Influence of ligands on the aggregation of the normal and mutant forms of phosphofructokinase 2 of Escherichia coli.

Authors:  V Guixé; J Babul
Journal:  Arch Biochem Biophys       Date:  1988-08-01       Impact factor: 4.013

6.  Solvent content of protein crystals.

Authors:  B W Matthews
Journal:  J Mol Biol       Date:  1968-04-28       Impact factor: 5.469

7.  Site-directed mutagenesis identifies catalytic residues in the active site of Escherichia coli phosphofructokinase.

Authors:  S A Berger; P R Evans
Journal:  Biochemistry       Date:  1992-09-29       Impact factor: 3.162

8.  Convergent evolution of similar enzymatic function on different protein folds: the hexokinase, ribokinase, and galactokinase families of sugar kinases.

Authors:  P Bork; C Sander; A Valencia
Journal:  Protein Sci       Date:  1993-01       Impact factor: 6.725

9.  Domain motions and quaternary packing of phosphofructokinase-2 from Escherichia coli studied by small angle x-ray scattering and homology modeling.

Authors:  Ricardo Cabrera; Hannes Fischer; Stefano Trapani; Aldo F Craievich; Richard C Garratt; Victoria Guixé; Jorge Babul
Journal:  J Biol Chem       Date:  2003-01-14       Impact factor: 5.157

10.  Crystal structure of the complex of phosphofructokinase from Escherichia coli with its reaction products.

Authors:  Y Shirakihara; P R Evans
Journal:  J Mol Biol       Date:  1988-12-20       Impact factor: 5.469

View more
  1 in total

1.  Nutritional and metabolic requirements for the infection of HeLa cells by Salmonella enterica serovar Typhimurium.

Authors:  Steven D Bowden; Amanda C Hopper-Chidlaw; Christopher J Rice; Vinoy K Ramachandran; David J Kelly; Arthur Thompson
Journal:  PLoS One       Date:  2014-05-05       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.